Share this article
Share this article
ResearchAndMarkets.com s offering.
The global market for DNA data storage should grow from $36.4 million in 2020 to $525.3 million by 2025 with a compound annual growth rate (CAGR) of 70.6% for the period of 2020-2025.
The scope of the report includes DNA data storage technologies, applications, industries, initiatives, patents and companies. The markets for DNA data storage products and services are given for the years 2019, 2020 and 2025 (forecast).
This report reviews the DNA data storage technologies, including DNA read and write technologies. It then discusses significant large-scale research initiatives that impact DNA storage, read and write applications. The main market driving forces for DNA data storage products and services are discussed.
Based on their analyses, the researchers are calling for prioritizing clinical trials of drugs targeting the proteins IFNAR2 and ACE2. The goal is to identify existing drugs, either FDA-approved or in clinical development for other conditions, that can be repurposed for the early management of COVID-19. Doing so, they say, will help keep people with the virus from being hospitalized.
IFNAR2 is the target for approved drugs often used by patients with relapsing forms of the central nervous system disorder multiple sclerosis. The researchers believe the most promising ACE2 therapy against COVID-19 is a drug that was developed before the pandemic began and has been evaluated in clinical trials to reduce inflammatory response in patients with severe respiratory disorders.
E-Mail
IMAGE: Dr. Juan P. Casas, a physician epidemiologist, led the study, which called for prioritizing clinical trials of drugs targeting two proteins. view more
Credit: Frank Curran
A new study using human genetics suggests researchers should prioritize clinical trials of drugs that target two proteins to manage COVID-19 in its early stages.
The findings appeared online in the journal
Nature Medicine in March 2021.
Based on their analyses, the researchers are calling for prioritizing clinical trials of drugs targeting the proteins IFNAR2 and ACE2. The goal is to identify existing drugs, either FDA-approved or in clinical development for other conditions, that can be repurposed for the early management of COVID-19. Doing so, they say, will help keep people with the virus from being hospitalized.
Abstract
The COVID-19 pandemic halted research operations at academic medical centers. This shutdown has adversely affected research infrastructure, the current research workforce, and the research pipeline. We discuss the impact of the pandemic on overall research operations, examine its disproportionate effect on underrepresented minority researchers, and provide concrete strategies to reverse these losses.
INTRODUCTION
In March 2020, the United States experienced the first peak of coronavirus disease 2019 (COVID-19) cases (
1). In an effort to flatten the curve of the ensuing COVID-19 pandemic, academic medical centers across the country reduced their operations by limiting patient care to urgent and emergent concerns, moving a large proportion of personnel to work virtually from home, and restricting operations not related to direct patient care or COVID-19. Although the initiatives taken to address the pandemic were essential, it is important to assess and understand the imp
Academic careers and the COVID-19 pandemic: Reversing the tide sciencemag.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencemag.org Daily Mail and Mail on Sunday newspapers.